| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2014-11-20 | Myriad Genetics (USA - UT) Tesaro (USA - MA) | myChoice HRD companion diagnostic and niraparib | collaboration |
Cancer - Oncology - Diagnostic | Collaboration agreement | |
| 2014-11-20 | Anthera Pharmaceuticals (USA - CA) Patheon® division of DPx Holdings (USA - NC) | Sollpura® | Exocrine Pancreatic Insufficiency (EPI), due to cystic fibrosis | manufacturing production |
Metabolic diseases - Rare diseases | Production agreement |
| 2014-11-20 | Ipsen (France) CNRS (France) | Archi-Pex (peptide architectures and formulations) joint research and innovation lab | collaboration |
Collaboration agreement | ||
| 2014-11-19 | Shire (UK - USA) | establishment of a new subsidiary in the US |
Rares diseases - CNS diseases - Gastrointestinal diseases | Establishment of a new subsidiary in the US | ||
| 2014-11-19 | Shire (UK - USA) | chief financial officer | nomination | Rares diseases - CNS diseases - Gastrointestinal diseases | Resignation | |
| 2014-11-19 | Cortendo (Sweden) | chief medical officer | nomination | Rare diseases | Nomination | |
| 2014-11-18 | Ipsen (France) Salk Institute (USA) | R&D |
Cancer - Oncology - Neurodegenerative diseases | R&D agreement | ||
| 2014-11-18 | Seattle Genetics (USA - WA) | vice-president | nomination | Cancer - Oncology | Nomination | |
| 2014-11-18 | Fermion, subsidiary of Orion (Finland) | president | nomination | Nomination | ||
| 2014-11-18 | Nosopharm (France) | scientific advisory board | nomination | Infectious diseases | Nomination | |
| 2014-11-18 | Stada (Germany) mAbxience (Switzerland) | adalimumab (Humira® biosimilar) | licensing |
Autoimmune diseases – Inflammatory diseases - Rheumatic diseases | Licensing agreement | |
| 2014-11-18 | Xellia Pharmaceuticals (Denmark) | active pharmaceutical ingredients (API) R&D Center of Excellence in Oslo | opening of new premises | Infectious diseases | Opening of new premises | |
| 2014-11-18 | Sanofi (France) | member of the board of directors | nomination | Nomination | ||
| 2014-11-18 | Illumina (USA - CA) bioMérieux (France) | next-generation sequencing (NGS) epidemiology solution for service labs | development |
Technology - Services - Infectious diseases | Development agreement | |
| 2014-11-18 | Ablynx (Belgium) | chief commercial officer | nomination | Nomination | ||
| 2014-11-17 | Bone Therapeutics (Belgium) Kasios (France) | novel product for spinal fusion procedures based on the combination of allogeneic osteoblastic cell therapy product ALLOB® with Kasios’s synthetic micro-granules bone substitute | spinal fusion | development |
Bone diseases | Development agreement |
| 2014-11-17 | Cardiome Pharma (Canada) Aspen Pharmacare (South Africa) | Brinavess® (vernakalant intravenous) | distribution |
Cardiovascular diseases | Distribution agreement | |
| 2014-11-17 | Valneva (France - Austria) undisclosed global pharmaceutical company | EB66® cell line | licensing R&D |
Infectious diseases | Licensing agreement | |
| 2014-11-17 | Valneva (France - Austria) undisclosed animal vaccine manufacturer (Japan) | EB66® cell line | licensing R&D |
Veterinary medicine | Licensing agreement | |
| 2014-11-17 | Clovis Oncology (USA - CO) GSK (UK) | combination of rociletinib (CO-1686) with trametinib | mutant epidermal growth factor receptor (EGFR) non-small cell lung cancer (NSCLC) | clinical research |
Cancer - Oncology | Clinical research agreement |
